Dr. Dominique Demolle, CEO, Company Co-Founder

Dominique Demolle has over 20 years of experience in Pharmaceutical Development. She received her PhD degree in Applied Biomedical Sciences from Free University of Brussels (ULB, Belgium).

Industry Experience:

In 1989, Dr Demolle jointed the Clinical Research group of GD Searle Belgium, where she managed efficacy trials, mainly in inflammatory diseases. In 1993, she jointed Eli Lilly, and in 1996 she was promoted to Research Scientist in Clinical Pharmacology.

From 1999, Dr Demolle held positions of increasing leadership responsibilities (from Local to Global). In 2003, she became in charge of the US Indianapolis Lilly CRU (Clinical Research Unit), in addition to the European Operational staff. In 2004, she was promoted to Associate Director of Global Early Phase Operations (with the Global Early Phase Lilly operational staff and the Lilly CRU reporting to her).

Dominique has an excellent knowledge of Drug Development in different therapeutic areas, as well as strong managerial skills. Because of her scientific background and understanding of compound development requirements, she reconciles "science" to operational constraints in the most efficient way.

In 2007, Dominique has left Lilly and has co-founded Aepodia with Denis Gossen and former colleagues/peers.